Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Eli Lilly Japan and Mitsubishi Tanabe Pharma Introduced Mounjaro® subcutaneous injection 2.5 mg / 5 mg ATEOS®

Eli Lilly Japan and Mitsubishi Tanabe Pharma Corporation has introduced “Mounjaro® subcutaneous injection 2.5 mg / 5 mg ATEOS®”.

The world's first long-acting GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist, Mounjaro is a first-in-class medicine that activates both the GLP-1 and GIP receptors.

The structure of the Mounjaro is based on a single molecule natural GIP peptide sequence, modified to bind to the GLP-1 receptor, and selectively acts for a long time to improve blood glucose. Mounjaro is a new class of treatment options for many people living with type 2 diabetes who need it.

Mounjaro with a single-use auto-injector (ATEOS) is delivered once in a week as a subcutaneous injection. The needle is inserted automatically consisting of a special pen with a pre-installed needle pressing the injection button under the skin and a single dose of the filled drug is injected with this needle. This injection does not require the patient to set the dose or handle the needle.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024